Literature DB >> 17997501

Cell-based drug delivery.

F Pierigè1, S Serafini, L Rossi, M Magnani.   

Abstract

Drug delivery has been greatly improved over the years by means of chemical and physical agents that increase bioavailability, improve pharmacokinetic and reduce toxicities. At the same time, cell based delivery systems have also been developed. These possesses a number of advantages including prolonged delivery times, targeting of drugs to specialized cell compartments and biocompatibility. Here we'll focus on erythrocyte-based drug delivery. These systems are especially efficient in releasing drugs in circulations for weeks, have a large capacity, can be easily processed and could accommodate traditional and biologic drugs. These carriers have also been used for delivering antigens and/or contrasting agents. Carrier erythrocytes have been evaluated in thousands of drug administration in humans proving safety and efficacy of the treatments. Erythrocyte-based delivery of new and conventional drugs is thus experiencing increasing interests in drug delivery and in managing complex pathologies especially when side effects could become serious issues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997501     DOI: 10.1016/j.addr.2007.08.029

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  53 in total

Review 1.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

2.  Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel.

Authors:  Gamaleldin I Harisa; Mohamed F Ibrahim; Fars Alanazi; Gamal A Shazly
Journal:  Saudi Pharm J       Date:  2013-01-07       Impact factor: 4.330

Review 3.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

4.  Drug delivery systems: Advanced technologies potentially applicable in personalized treatments.

Authors:  Jorge F Coelho; Paula C Ferreira; Patricia Alves; Rosemeyre Cordeiro; Ana C Fonseca; Joana R Góis; Maria H Gil
Journal:  EPMA J       Date:  2010-04-10       Impact factor: 6.543

Review 5.  Erythrocyte-mediated delivery of recombinant enzymes.

Authors:  Vincenzo Leuzzi; Luigia Rossi; Claudia Gabucci; Francesca Nardecchia; Mauro Magnani
Journal:  J Inherit Metab Dis       Date:  2016-03-30       Impact factor: 4.982

Review 6.  Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.

Authors:  Carlos H Villa; Douglas B Cines; Don L Siegel; Vladimir Muzykantov
Journal:  Transfus Med Rev       Date:  2016-08-17

Review 7.  Improving cell-based therapies by nanomodification.

Authors:  Wei Chen; Liwu Fu; Xiaoyuan Chen
Journal:  J Control Release       Date:  2015-09-28       Impact factor: 9.776

8.  Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults.

Authors:  Michael R Flock; Ann C Skulas-Ray; William S Harris; Trent L Gaugler; Jennifer A Fleming; Penny M Kris-Etherton
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-07-17       Impact factor: 4.006

Review 9.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

Review 10.  Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles.

Authors:  Aaron C Anselmo; Samir Mitragotri
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.